Skip to main content

Research Repository

Advanced Search

Towards Personalized Management of Ovarian Cancer

Algethami, Mashael; Kulkarni, Sanat; Sadiq, Maaz T; Tang, Hiu KC; Brownlie, Juliette; Jeyapalan, Jennie N; Mongan, Nigel P; Rakha, Emad A; Madhusudan, Srinivasan


Mashael Algethami

Sanat Kulkarni

Maaz T Sadiq

Hiu KC Tang

Juliette Brownlie

Jennie N Jeyapalan

Professor of Oncology

Emad A Rakha


Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60–80%, most patients will have recurrence and succumb to the disease. However, a DNA repair–directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.


Algethami, M., Kulkarni, S., Sadiq, M. T., Tang, H. K., Brownlie, J., Jeyapalan, J. N., …Madhusudan, S. (2022). Towards Personalized Management of Ovarian Cancer. Cancer Management and Research, 14, 3469-3483.

Journal Article Type Review
Acceptance Date Dec 10, 2022
Online Publication Date Dec 15, 2022
Publication Date 2022
Deposit Date Apr 9, 2023
Publicly Available Date Apr 18, 2023
Journal Cancer Management and Research
Print ISSN 1179-1322
Publisher Informa UK Limited
Peer Reviewed Peer Reviewed
Volume 14
Pages 3469-3483
Keywords Oncology
Public URL
Publisher URL


You might also like

Downloadable Citations